



Press release Stockholm 2025-06-16 08:30 CET

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Kancera AB (publ) (Kancera) announces that the World Health Organization has granted rugocrixan and fosrugocrixan as the International Non-proprietary Names for the company's candidate drugs KAND567 and KAND145.

An International Non-proprietary Name (INN) is a unique, globally recognized name for a pharmaceutical drug or active ingredient. Each active substance that is to be marketed as a pharmaceutical product must be granted a unique name of worldwide acceptability to ensure the clear identification, safe prescription and dispensing of medicines to patients. INNs are intended for wide use ranging from labelling and product information to drug regulation and scientific literature.

The World Health Organization (WHO) has granted rugocrixan as the INN for KAND567 and fosrugocrixan as the INN for KAND145, in accordance with the WHO's procedure for the selection of recommended INNs for pharmaceutical substances.

The declaration of the new and unique suffix stem "-crixan" identifies a new class of drugs that are small molecule CX3CR1 antagonists. The prefix stem "fos-" is identified for use for phosphoro-derivatives and has been used to indicate prodrugs. As KAND145 is a phosphor-prodrug of KAND567, the nomenclature -fosrugocrixan is appropriate for use in its INN.

The mode of action of rugocrixan and fosrugocrixan is to target and block CX3CR1, the fractalkine receptor, and thereby control levels of certain specific immune cells that are disease promoting in various inflammatory conditions, cancers and autoimmune diseases. The fact that the WHO has granted a new and unique suffix stem to Kancera's candidate drugs means that they constitute an own new class of drugs and they are the first substances to be named by the WHO in this class.

"Kancera is a world leading pioneer in the field of small molecule CX3CR1 antagonists. This is now manifested with our candidate drugs setting the international name standard for this new class of drugs," says Peter Selin, CEO at Kancera.

About Kancera AB (publ)

Kancera is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action with focus on cardiovascular diseases. The stock is traded on the Nasdaq First North Premier Growth Market. Redeye AB is the company's Certified Adviser and can be contacted at certifiedadviser@redeye.se.

For further information:

Visit Kancera's website: www.kancera.com

or **contact:**

ir@kancera.com or phone: +46 (0)8-5012 60 80